Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Robenacoxib is a novel and highly selective inhibitor of COX-2 in dogs and cats and because of its acidic nature is regarded as being tissue-selective. Thirty four dogs with stifle osteoarthritis secondary to failure of the cranial cruciate ligament were recruited into this study. Lameness, radiographic features, synovial cytology and C-reactive protein concentrations in serum and synovial fluid were assessed before and 28 days after commencing a course of Robenacoxib at a dose of 1 mg/kg SID. RESULTS: There was a significant reduction in the lameness score (P 

Original publication




Journal article


BMC Vet Res

Publication Date





Animals, C-Reactive Protein, Cyclooxygenase Inhibitors, Diphenylamine, Dog Diseases, Dogs, Female, Lameness, Animal, Male, Osteoarthritis, Phenylacetates, Radiography, Stifle, Synovial Fluid